 Objectives: 1 To evaluate la proportion of hepatitic C virus HCV-monoinfected patients who show sustained virologic response SVR to treatment including direct-acting antivirals DAAs in the clinical practice in clinical units that treat infectious diseases and 2 to determine the frequency of adverse events, including those that are severe andor cause treatment interruption, in DAA-based therapy in this setting. 